RegrowProtocol

Trial pipeline · NCT04594018

Efficacy and Safety of Finlândia Hair Lotion Association on Androgenetic Alopecia

Phase 3 Recruiting status last verified 2025-12

A registered clinical trial, reproduced from its ClinicalTrials.gov record. Every value on this page is a field on that record. Nothing on this page is a finding, an assessment or a recommendation.

The registered record

Accession number
NCT04594018
Lead sponsor
EMS (industry)
Registered condition naming hair loss
Androgenetic Alopecia
Official title
National, Multicentre, Randomized, Double-blind, Double-dummy Phase III Clinical Trial to Evaluate the Efficacy and Safety of Finlândia Hair Lotion Association in the Treatment of Androgenetic Alopecia.

Interventions

  • DrugFinlândia Association + finasteride placebo
  • DrugMinoxidil + finasteride

Names and types as registered. The sponsors' free-text descriptions of these interventions are not reproduced: they are written by the party with an interest in the result, and reprinting them inside this site's layout would lend them this site's voice.

Design

Study type
interventional
Phase
Phase 3
Allocation
randomized
Masking
double
Primary purpose
treatment
Enrolment
190 participants (estimated)
Sites
1 location in Brazil

What it measures

  1. Change from baseline in hair density.

    Time frame: 6 months

Primary outcome measures only, as registered. What a trial chose to measure, and when, is the most informative thing about it that is knowable before it reports — a hair-count endpoint at 24 weeks and a patient-satisfaction endpoint at 12 weeks are not the same study.

Who can take part

Sex
male
Age
18 Years to 60 Years
Healthy volunteers
not accepted

A summary of three registered fields, not the eligibility criteria. The full inclusion and exclusion criteria, the recruiting sites and the study contacts are on the registry record, which is the only place they are maintained. This site has no relationship with this trial and cannot refer anyone to it.

Registered dates

Study start
2 February 2023 (actual)
Primary completion
May 2026 (estimated)
Study completion
September 2027 (estimated)
First posted
20 October 2020 (actual)
Last update posted
8 December 2025 (actual)

"Estimated" and "actual" are the registry's own labels: an estimated date is a plan, and plans move. A date is printed at the precision it was registered at: a primary completion registered as 2026-05 is a month, and rendering it as 1 May 2026 would invent a day the sponsor did not register.

Results

This trial has not reported results. ClinicalTrials.gov holds no results record for it. That is the ordinary state of a trial that is running or about to run, and it means there is nothing here to tell you about whether the intervention works — including nothing negative. If this page implied otherwise it would be wrong.

On this site

Guides covering the condition this trial is registered for. They are about published evidence; this page is about a registration, and the two do not overlap.

Where this came from

Read from the ClinicalTrials.gov API on 6 September 2026 and rebuilt into this page without alteration. ClinicalTrials.gov is a service of the U.S. National Library of Medicine and is the authority on this record; where this page and the registry disagree, the registry is right. This page is not affiliated with or endorsed by NLM or NIH, or with the sponsor of this trial.

Open NCT04594018 on ClinicalTrials.gov · All 157 trials in the pipeline